Efficacy and safety of the RTS,S/AS01 malaria vaccine during 18 months after vaccination: a phase 3 randomized, controlled trial in children and young infants at 11 African sites
about
Do advanced glycation end-products play a role in malaria susceptibility?The clinical development process for a novel preventive vaccine: An overviewEthical aspects of malaria control and researchProfiling the host response to malaria vaccination and malaria challengePaths to a malaria vaccine illuminated by parasite genomicsVaccines against malariaThe time-course of protection of the RTS,S vaccine against malaria infections and clinical diseaseIdentification of Novel Pre-Erythrocytic Malaria Antigen Candidates for Combination Vaccines with Circumsporozoite ProteinAlternatives to currently used antimalarial drugs: in search of a magic bulletDelivering vaccines to the people who need them mostMalaria vaccine clinical trials: what's on the horizonThe March Toward Malaria VaccinesDomestic trends in malaria research and development in China and its global influencePotential public health impact of RTS,S malaria candidate vaccine in sub-Saharan Africa: a modelling studyThe public health impact of malaria vaccine RTS,S in malaria endemic Africa: country-specific predictions using 18 month follow-up Phase III data and simulation models.Immunogenicity of the RTS,S/AS01 malaria vaccine and implications for duration of vaccine efficacy: secondary analysis of data from a phase 3 randomised controlled trialCosting RTS,S introduction in Burkina Faso, Ghana, Kenya, Senegal, Tanzania, and Uganda: A generalizable approach drawing on publicly available data.Rational development of a protective P. vivax vaccine evaluated with transgenic rodent parasite challenge models.Enhancing protective immunity to malaria with a highly immunogenic virus-like particle vaccine.Virus-Like Particle (VLP) Plus Microcrystalline Tyrosine (MCT) Adjuvants Enhance Vaccine Efficacy Improving T and B Cell Immunogenicity and Protection against Plasmodium berghei/vivax.Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial.Efficacy of Phase 3 Trial of RTS, S/AS01 Malaria Vaccine in infants: a systematic review and meta-analysis.Genetic polymorphism and amino acid sequence variation in Plasmodium falciparum GLURP R2 repeat region in Assam, India, at an interval of five yearsCalibration of an intrahost malaria model and parameter ensemble evaluation of a pre-erythrocytic vaccine.The effect of immunization schedule with the malaria vaccine candidate RTS,S/AS01E on protective efficacy and anti-circumsporozoite protein antibody avidity in African infantsImpact of malaria preexposure on antiparasite cellular and humoral immune responses after controlled human malaria infection.Malaria Vaccines: Moving Forward After Encouraging First Steps.Malaria-associated atypical memory B cells exhibit markedly reduced B cell receptor signaling and effector function.Malaria Vaccines: Progressing on a Bumpy Road.Malaria eradication and elimination: views on how to translate a vision into realityComparative assessment of vaccine vectors encoding ten malaria antigens identifies two protective liver-stage candidates.Nanoparticulate STING agonists are potent lymph node-targeted vaccine adjuvants.Assessment of parental perception of malaria vaccine in Tanzania.Nanovaccines for malaria using Plasmodium falciparum antigen Pfs25 attached gold nanoparticles.Transcriptional changes induced by candidate malaria vaccines and correlation with protection against malaria in a human challenge model.Safety and Immunogenicity of Pfs25-EPA/Alhydrogel®, a Transmission Blocking Vaccine against Plasmodium falciparum: An Open Label Study in Malaria Naïve Adults.Circulating Th1-Cell-type Tfh Cells that Exhibit Impaired B Cell Help Are Preferentially Activated during Acute Malaria in Children.Probability of Transmission of Malaria from Mosquito to Human Is Regulated by Mosquito Parasite Density in Naïve and Vaccinated HostsModification of Asparagine-Linked Glycan Density for the Design of Hepatitis B Virus Virus-Like Particles with Enhanced Immunogenicity.Enhancing immunogenicity and transmission-blocking activity of malaria vaccines by fusing Pfs25 to IMX313 multimerization technology
P2860
Q24471760-D4BC8750-E9B3-4A38-ABE3-7FA787C93337Q26770871-2A7108EF-0E26-4F84-8318-0A42F07F81D0Q26773470-659AFCE4-63E6-4528-AA28-E0A124BBE4BAQ26800494-81A153E3-1304-4F2F-95E7-12548588DF8AQ26853267-79C9F2B8-AD5B-4AAF-AE8B-141E20B0533DQ26995079-83ECCB9F-5984-4539-A66D-A740FA9FEE9AQ27304630-CE75159C-ABB0-4FB0-BC5A-F89CE8E8A2CAQ27973488-F019434C-70AD-43F8-9146-835259C4FF41Q28070398-615904FF-5B72-44F3-9D46-08421A7F11B7Q28082744-31E59803-8B11-4256-970A-B792D2FF9D11Q28083110-7A33A57A-9B12-4AEA-8925-D8B114D95971Q28084325-CA2C1EAC-BCCC-4B28-BE85-BF87FCB5593CQ28365208-090F390B-31D4-4D6F-91CE-2B596FEE396CQ28397448-062957FB-A8CE-4AC3-B394-120CBD50DB84Q30983587-3B3520F0-4148-49CA-AF5F-FC7703FB2AC3Q30991737-23D7013B-1090-4376-BEEF-92F37F57C538Q31013590-1C85F7E7-7121-406B-9022-F2AD793D3827Q33572458-D8F92344-C509-4580-A271-357E2FE028DDQ33577093-E7B8D504-B62D-4FFB-87DA-D07D53643DA4Q33855899-8C0F92CD-749D-4564-BFE6-86AA1CB309DCQ34043843-8C72DFDA-07ED-48A3-A492-429C08CAED9CQ34548672-A05CA0A8-E181-4EF2-92A0-96BD2547AED8Q34636542-A00ADB57-5B20-44CC-8299-0C4DFCA38157Q35079044-2CD66898-A0AA-47F1-9006-0B4C1C612C1BQ35105075-7BEFAB2B-CDFC-40B5-B770-8E2721174E44Q35439859-1227CB5D-A9E3-4118-BAB0-C2E532F69BC5Q35619891-6F714561-1772-472A-9CC8-99E99A317321Q35649750-FED14220-BA86-4A54-8CC8-B54883C01835Q35688171-95BD9E16-F0C6-48AB-86F3-A0FAACC51068Q35712522-CAE06969-0DDB-448D-910E-1318A24CC299Q35813430-32911438-E156-4243-A38C-A580EFD35837Q35836140-E5623C84-94B1-45A8-9A9A-C32C4C541590Q36068819-3FFEA7D8-24D8-4D2D-A68C-BF534D665655Q36079818-3E2CF88A-9B59-468B-B20D-ABFF62030B85Q36092323-D7BDF396-E680-435A-BD94-AFEF8305C626Q36165265-131E2BB0-012B-404C-8E9B-FF4A222AF827Q36167295-2190F359-79D6-4909-B078-84EEB73EFEA7Q36247867-5D73DD42-7897-4D99-A131-2A8DF1D8EA65Q36281860-64C9251D-5ADD-492C-8F41-E396A8915E8DQ36442817-68831C74-7173-40E2-A038-74C06D014C5D
P2860
Efficacy and safety of the RTS,S/AS01 malaria vaccine during 18 months after vaccination: a phase 3 randomized, controlled trial in children and young infants at 11 African sites
description
2014 nî lūn-bûn
@nan
2014 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Efficacy and safety of the RTS ...... ng infants at 11 African sites
@ast
Efficacy and safety of the RTS ...... ng infants at 11 African sites
@en
Efficacy and safety of the RTS ...... ng infants at 11 African sites
@nl
type
label
Efficacy and safety of the RTS ...... ng infants at 11 African sites
@ast
Efficacy and safety of the RTS ...... ng infants at 11 African sites
@en
Efficacy and safety of the RTS ...... ng infants at 11 African sites
@nl
prefLabel
Efficacy and safety of the RTS ...... ng infants at 11 African sites
@ast
Efficacy and safety of the RTS ...... ng infants at 11 African sites
@en
Efficacy and safety of the RTS ...... ng infants at 11 African sites
@nl
P2860
P3181
P1433
P1476
Efficacy and safety of the RTS ...... ng infants at 11 African sites
@en
P2860
P304
P3181
P356
10.1371/JOURNAL.PMED.1001685
P407
P577
2014-07-01T00:00:00Z